Sign inCreate account

Report workspace

Add to folder
NCT07609485RECRUITINGanonymous

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy at the CHU, Lille: Biological Prospective Collection and Storage

Sponsor

Source record

University Hospital, Lille

Phase

Source record

Observational

Modality

AI-normalized

cell therapy

Target

AI-normalized

Cellular and molecular determinants influencing CAR-T cell efficacy and resistance, including factors affecting homing and persistence of CAR-T cells in vivo.

Indication / condition

AI-normalized

Cancer

Intervention

Source record

Detailed source ingestion pending.

Source & freshness

Source record

NCT ID

NCT07609485

Original source

ClinicalTrials.gov

Source last updated

May 27, 2026

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07609485

Title

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy at the CHU, Lille: Biological Prospective Collection and Storage

Sponsor

University Hospital, Lille

Status

RECRUITING

Phase

Observational

Condition raw

Cancer, Hematologic Malignancy

Condition normalized

Cancer, Hematologic Malignancy

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

Cellular and molecular determinants influencing CAR-T cell efficacy and resistance, including factors affecting homing and persistence of CAR-T cells in vivo.

Target normalized

Cellular and molecular determinants influencing CAR-T cell efficacy and resistance, including factors affecting homing and persistence of CAR-T cells in vivo.

Interventions

Detailed source ingestion pending

Public preview

Source record

This observational study aims to identify biomarkers and cellular factors that influence the efficacy and durability of CAR-T therapies in patients with hematologic malignancies. With an estimated enrollment of 700 patients, the findings could significantly enhance patient selection and treatment personalization, potentially leading to improved response rates and reduced relapse. The study's outcomes may provide valuable insights for pharmaceutical companies developing next-generation CAR-T therapies, positioning them competitively in a rapidly evolving market. The focus on durable responses aligns with industry trends towards personalized medicine, making this research critical for stakeholders in the CAR-T space.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy at the CHU, Lille: Biological Prospective Collection and Storage

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT07609485

Status

RECRUITING

Phase

Observational

Sponsor

University Hospital, Lille

Executive brief

Investment-Ready Snapshot

This observational study aims to identify biomarkers and cellular factors that influence the efficacy and durability of CAR-T therapies in patients with hematologic malignancies. With an estimated enrollment of 700 patients, the findings could significantly enhance patient selection and treatment personalization, potentially leading to improved response rates and reduced relapse. The study's outcomes may provide valuable insights for pharmaceutical companies developing next-generation CAR-T therapies, positioning them competitively in a rapidly evolving market. The focus on durable responses aligns with industry trends towards personalized medicine, making this research critical for stakeholders in the CAR-T space.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 27, 2026
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07609485

Indication

Cancer

Modality

cell therapy

Target

Cellular and molecular determinants influencing CAR-T cell efficacy and resistance, including factors affecting homing and persistence of CAR-T cells in vivo.

Intervention

Not reported

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.